Broken String

Broken String Biosciences Appoints Gavin Burns as Vice President of Quality and Operations

Retrieved on: 
Wednesday, November 22, 2023
Health, Biometrics, Genetics, Research, Science, Biotechnology, Associate, Quality, DNA, Gene editing, DNA sequencing, Series, Danco Island, Broken, Growth, Doctor of Philosophy, NGS, British Antarctic Survey, University of Gothenburg, Broken String, Genomics

Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations.

Key Points: 
  • Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations.
  • With an extensive background leading quality assurance in the genomics sector, Gavin will be responsible for building and optimizing Broken String’s teams, processes, and systems.
  • Prior to joining Broken String, Gavin held senior quality and operational roles at several UK-based start-ups, most recently serving as Director of Quality and Operations at Biocrucible.
  • To learn more about Broken String Biosciences, please visit brokenstringbio.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231122788308/en/

Broken String Biosciences’ INDUCE-seq Platform Demonstrates Impact of Structural DNA Changes on Specificity of CRISPR-Cas9 Gene Editing

Retrieved on: 
Wednesday, October 18, 2023
Health, Genetics, Health Technology, Research, Science, Biotechnology, Newton, Gene editing, CRISPR, Genomics, Genome, Doctor of Philosophy, Cell, Broken String, DNA, Vaccine, Molecular Cell, Cas9

Published in Molecular Cell, the research highlights DNA topology as a key regulator to CRISPR targeting specificity that must be carefully considered during development of CRISPR-based therapies.

Key Points: 
  • Published in Molecular Cell, the research highlights DNA topology as a key regulator to CRISPR targeting specificity that must be carefully considered during development of CRISPR-based therapies.
  • Since its discovery, the CRISPR-Cas9 system has enabled researchers to elicit precise DNA edits at virtually any site across the genome.
  • The new study was co-authored by a team of scientists, including Broken String co-founders Professor Simon Reed and Patrick van Eijk, PhD.
  • Professor Simon Reed, Chief Scientific Officer, Broken String Biosciences, remarked: "This study demonstrates the importance of measuring off-target gene editing activity directly in the cells that are being edited.

Broken String Biosciences Strengthens Senior Leadership Team to Accelerate Product Development and Commercialization

Retrieved on: 
Monday, October 2, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Acceleration, University of Oxford, Trade, Broken String, Central New York Regional Market, NGS, Gene editing, Genomics, Doctor of Philosophy, Chemistry, Vincent Smith, Traction, Broken, Consumables, Commercial, Vince, Imperial College London, Management, Vaccine, Illumina, Inc., Illumina, Biochemistry

As CTO at Broken String, Vince will lead product development, providing leadership and the expertise required to build INDUCE-seq into the gold standard technology for the assessment of off-target effects during gene editing.

Key Points: 
  • As CTO at Broken String, Vince will lead product development, providing leadership and the expertise required to build INDUCE-seq into the gold standard technology for the assessment of off-target effects during gene editing.
  • Jessica will oversee the development of commercialization strategy, enabling the Company to capitalize on early commercial traction and accelerate growth across the US, Europe and Asia.
  • Before joining Broken String, Jessica held several senior leadership roles, including Senior Director of Sales and Regional Marketing at Bionano, Senior Director of Commercial Development at Synthego and Chief Commercial Officer at 54gene.
  • Jessica Rich, VP Business Development at Broken String Biosciences, said: "I am excited to join the team at Broken String Biosciences and to expand the global commercial footprint from my base in Boston, MA.

Broken String Biosciences Closes $15M Series A Funding Round

Retrieved on: 
Monday, September 18, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, DNA, Platform as a service, Broken String, Investment, Wellcome Genome Campus, NGS, Gene editing, Tencent, Genomics, Doctor of Philosophy, Cas9, Traction, Patient, Polymerase chain reaction, National Human Genome Research Institute, Biology, Growth, Safety, PCR, Genome, Data science, Antibiotics, Vaccine

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures).

Key Points: 
  • Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures).
  • As part of the round, Yoann Bonnamour, Mérieux Equity Partners, and Arnaud Autret, Illumina Ventures, join the Company’s Board of Directors.
  • Felix Dobbs, PhD, Chief Executive Officer of Broken String Biosciences, commented: “Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients.
  • This new funding will enable the technology to be developed and delivered in a format that meets the needs of all customers, ideally positioning the Company for significant growth.”
    To learn more about Broken String Biosciences, please visit brokenstringbio.com